An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in gremlin <em>BRCA</em>-mutated (<em>gBRCA</em>m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Drew, Y; de, Jonge, M; Hong, SH; Park, YH; Wolfer, A; Brown, J; Ferguson, M; Gore, ME; Alvarez, RH; Gresty, C; Angell, H; Meyer, K; Learoyd, M; Tang, M; Lanasa, M; Herbolsheimer, P; Domchek, SM

doi:10.1016/j.ygyno.2018.04.555

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in gremlin BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Lookup NU author(s): Dr Yvette Drew ORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Publication metadata

Author(s): Drew Y, de Jonge M, Hong SH, Park YH, Wolfer A, Brown J, Ferguson M, Gore ME, Alvarez RH, Gresty C, Angell H, Meyer K, Learoyd M, Tang M, Lanasa M, Herbolsheimer P, Domchek SM

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: 49th Annual Meeting of the Society of Gynecologic Oncology

Year of Conference: 2018

Pages: 246-247

Online publication date: 25/06/2018

Acceptance date: 02/02/2018

ISSN: 0090-8258

Publisher: Elsevier

URL: https://doi.org/10.1016/j.ygyno.2018.04.555

DOI: 10.1016/j.ygyno.2018.04.555

Series Title: Gynecologic Oncology

ePrints

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in gremlin BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Downloads

Publication metadata

Share